Frank Karbe, Director at Arbutus Biopharma, holds 57.00K shares in Phathom Pharmaceuticals (Ticker: PHAT), holds 526.52K shares in Better Therapeutics, Inc. (Ticker: BTTX), holds 212.30K shares in Myovant Sciences (Ticker: MYOV). Most recently, Frank Karbe Bought ― shares of Phathom Pharmaceuticals on Dec 16, 2024 for an estimated value of 99.00K.
What is the percentage of profitable transactions made by Frank Karbe?
The percentage of profitable transactions made by Frank Karbe is 60%.
What is the average return per transaction made by Frank Karbe?
The average return per transaction made by Frank Karbe is -3.30%.
What stocks does Frank Karbe hold?
Frank Karbe holds: ABUS, MYOV, KDNY, PHAT, BTTX, EXEL stocks.
What was Frank Karbe’s latest transaction?
Frank Karbe latest transaction was an Informative Buy of $99.00K.
What was Frank Karbe's most profitable transaction?
Frank Karbe’s most profitable transaction was an Informative Buy of MYOV stock on June 11, 2019. The return on the trade was 76.00%.
What is Frank Karbe's role in Arbutus Biopharma?
Frank Karbe's role in Arbutus Biopharma is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.